Comparison of Bimatoprost 0.03% and Brimonidine 0.2% in Managing Intraocular Pressure Elevation Following Nd: YAG Laser Capsulotomy for Posterior Capsule Opacification.

IF 0.7 Q4 PHARMACOLOGY & PHARMACY Journal of pharmacy & bioallied sciences Pub Date : 2024-12-01 Epub Date: 2024-08-20 DOI:10.4103/jpbs.jpbs_605_24

Tulika Gupta, Rupali Kashyap, Shikhar Ganjoo

{"title":"Comparison of Bimatoprost 0.03% and Brimonidine 0.2% in Managing Intraocular Pressure Elevation Following Nd: YAG Laser Capsulotomy for Posterior Capsule Opacification.","authors":"Tulika Gupta, Rupali Kashyap, Shikhar Ganjoo","doi":"10.4103/jpbs.jpbs_605_24","DOIUrl":null,"url":null,"abstract":"Background: Posterior capsule opacification (PCO) is the most common cause of vision reduction following successful cataract surgery. It is a dynamic process caused by the migration and proliferation of residual lens epithelial cells on the posterior capsule, leading to visual impairment. The standard treatment for PCO is neodymium: yttrium-aluminum-garnet (Nd: YAG) laser capsulotomy. This study aims to compare the efficacy and safety of Bimatoprost 0.03% and Brimonidine 0.2% in preventing intraocular pressure (IOP) elevation post-Nd: YAG laser capsulotomy.Materials and methods: This study was conducted over a year at the Government Medical College, Jammu. 400 patients with PCO post extracapsular cataract extraction were randomly divided into two groups. Group A received 1 drop of Bimatoprost 0.03% and Group B received 1 drop of Brimonidine 0.2%, both administered 1 hour before Nd: YAG laser capsulotomy. Intraocular pressure was measured using Goldmann applanation tonometry before treatment and at intervals of 1 hour, 3 hours, 24 hours, 3 days, and 7 days post-treatment.Results: The mean age of patients was approximately 65 years with no significant difference between groups. The baseline IOP was similar across both groups. At 1 hour post-capsulotomy, Group A showed a mean IOP increase of 2.2 mmHg, while Group B showed an increase of 3.6 mmHg. At 24 hours, the IOP in Group A returned to baseline levels, whereas Group B still exhibited a slight elevation. No significant adverse effects were reported in either group.Conclusion: Bimatoprost 0.03% is more effective in preventing IOP elevation post Nd: YAG laser capsulotomy compared to Brimonidine 0.2%. It also demonstrated a faster return to baseline IOP levels with fewer side effects. This suggests that Bimatoprost may be a preferable prophylactic treatment for managing post-capsulotomy IOP spikes.","PeriodicalId":94339,"journal":{"name":"Journal of pharmacy & bioallied sciences","volume":"16 Suppl 4","pages":"S3142-S3145"},"PeriodicalIF":0.7000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11805283/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of pharmacy & bioallied sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/jpbs.jpbs_605_24","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/20 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Posterior capsule opacification (PCO) is the most common cause of vision reduction following successful cataract surgery. It is a dynamic process caused by the migration and proliferation of residual lens epithelial cells on the posterior capsule, leading to visual impairment. The standard treatment for PCO is neodymium: yttrium-aluminum-garnet (Nd: YAG) laser capsulotomy. This study aims to compare the efficacy and safety of Bimatoprost 0.03% and Brimonidine 0.2% in preventing intraocular pressure (IOP) elevation post-Nd: YAG laser capsulotomy.

Materials and methods: This study was conducted over a year at the Government Medical College, Jammu. 400 patients with PCO post extracapsular cataract extraction were randomly divided into two groups. Group A received 1 drop of Bimatoprost 0.03% and Group B received 1 drop of Brimonidine 0.2%, both administered 1 hour before Nd: YAG laser capsulotomy. Intraocular pressure was measured using Goldmann applanation tonometry before treatment and at intervals of 1 hour, 3 hours, 24 hours, 3 days, and 7 days post-treatment.

Results: The mean age of patients was approximately 65 years with no significant difference between groups. The baseline IOP was similar across both groups. At 1 hour post-capsulotomy, Group A showed a mean IOP increase of 2.2 mmHg, while Group B showed an increase of 3.6 mmHg. At 24 hours, the IOP in Group A returned to baseline levels, whereas Group B still exhibited a slight elevation. No significant adverse effects were reported in either group.

Conclusion: Bimatoprost 0.03% is more effective in preventing IOP elevation post Nd: YAG laser capsulotomy compared to Brimonidine 0.2%. It also demonstrated a faster return to baseline IOP levels with fewer side effects. This suggests that Bimatoprost may be a preferable prophylactic treatment for managing post-capsulotomy IOP spikes.

查看原文